Innovation Pharmaceuticals Inc (IPIX)

[DrBones]

I have been thinking about the numbers in the presentation from today and the last RR. According to last years conference:

Kevetrin activated p21 in 4 out of 5 patients treated with 20 or 30 mg/m2

A total of 18 patients had been "enrolled" at the time. The trial was currently dosing the 5th cohort.

Today's presentation states that p21 increased > 10% in 6 of 14 patients at "relatively low doses."

It's obvious that the 8th cohort was not included in p21 testing. Given 3 patients per cohort at a minimum, and having enrolled 18 by cohort 5, our patient totals should be approximately:

Cohort 6: 21 patients
Cohort 7: 24 patients
Cohort 8: 27 patients

Where are today's numbers coming from? If 18 had already been "enrolled" by the 5th cohort, shouldn't we have a larger sampling than 14 for the p21 results?